GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BriaCell Therapeutics Corp (FRA:8BT0) » Definitions » Gross Margin %

BriaCell Therapeutics (FRA:8BT0) Gross Margin % : 0.00% (As of Jan. 2025)


View and export this data going back to 2015. Start your Free Trial

What is BriaCell Therapeutics Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. BriaCell Therapeutics's Gross Profit for the three months ended in Jan. 2025 was €0.00 Mil. BriaCell Therapeutics's Revenue for the three months ended in Jan. 2025 was €0.00 Mil. Therefore, BriaCell Therapeutics's Gross Margin % for the quarter that ended in Jan. 2025 was 0.00%. If there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.


The historical rank and industry rank for BriaCell Therapeutics's Gross Margin % or its related term are showing as below:


FRA:8BT0's Gross Margin % is not ranked *
in the Biotechnology industry.
Industry Median: 59.475
* Ranked among companies with meaningful Gross Margin % only.

BriaCell Therapeutics had a gross margin of N/A% for the quarter that ended in Jan. 2025 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for BriaCell Therapeutics was 0.00% per year.


BriaCell Therapeutics Gross Margin % Historical Data

The historical data trend for BriaCell Therapeutics's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BriaCell Therapeutics Gross Margin % Chart

BriaCell Therapeutics Annual Data
Trend Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

BriaCell Therapeutics Quarterly Data
Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of BriaCell Therapeutics's Gross Margin %

For the Biotechnology subindustry, BriaCell Therapeutics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BriaCell Therapeutics's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BriaCell Therapeutics's Gross Margin % distribution charts can be found below:

* The bar in red indicates where BriaCell Therapeutics's Gross Margin % falls into.


;
;

BriaCell Therapeutics Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

BriaCell Therapeutics's Gross Margin for the fiscal year that ended in Jul. 2024 is calculated as

Gross Margin % (A: Jul. 2024 )=Gross Profit (A: Jul. 2024 ) / Revenue (A: Jul. 2024 )
=0 / 0
=(Revenue - Cost of Goods Sold) / Revenue
=(0 - 0) / 0
=N/A %

BriaCell Therapeutics's Gross Margin for the quarter that ended in Jan. 2025 is calculated as


Gross Margin % (Q: Jan. 2025 )=Gross Profit (Q: Jan. 2025 ) / Revenue (Q: Jan. 2025 )
=0 / 0
=(Revenue - Cost of Goods Sold) / Revenue
=(0 - 0) / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


BriaCell Therapeutics  (FRA:8BT0) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

BriaCell Therapeutics had a gross margin of N/A% for the quarter that ended in Jan. 2025 => No sustainable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


BriaCell Therapeutics Gross Margin % Related Terms

Thank you for viewing the detailed overview of BriaCell Therapeutics's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


BriaCell Therapeutics Business Description

Traded in Other Exchanges
Address
235-15th Street, Suite 300, 3rd Floor, Bellevue Centre, West Vancouver, Vancouver, BC, CAN, V7T 2X1
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.

BriaCell Therapeutics Headlines

No Headlines